Transtorno Obsessivo Compulsivo


Transtorno Obsessivo Compulsivo


Dennys Lapenda Fagundes

Psychiatric and Sleep Doctor. Master in Neuropsychiatry in Federal University of Pernambuco. CBT Specialist


Psychiatric Research and Reviews1

Obsessive Compulsive Disorder (OCD) is a disease that affects many psychopathological segments with the predominance of obsessive ideas or uncontrollable behaviors. Obsessions are presented as intrusive thoughts that cause increased anxiety; while compulsions present themselves as repetitive behaviors or mental acts aimed at minimizing anxiety. OCD was considered a very rare and poor prognosis, but with advances in scientific research, this concept is in the process of changing.


Keywords: Transtorno Obsessivo Compulsivo, Obsessive Compulsive Disorder


Free Full-text PDF


How to cite this article:
Dennys Lapenda Fagundes. Transtorno Obsessivo Compulsivo. International Journal of Psychological Research and Reviews, 2020; 3:41. DOI: 10.28933/ijprr-2020-08-1005


References

1. Berrios GE. Historia de los trastornos obsesivos. In: Ruiloba JV, Berrios GE editores. 2. ed. Estados obsesivos. Barcelona: Masson; 1995. p. 1-14.
2. American Psychiatry Association. Diagnostic and Statistical Manual for Psychiatry Disorders: DSM-V. 5th ed. Washington: APA; 2013.
3. Weissmann MM, Bland RC, Canino GJ, Greenwald S, Hwu HG, Lee CK, et al. The cross national epidemiology of obsessive compulsive disorder: the cross national collaborative group. J Clin Psychiatry. 1994;55(3):5-10.
4. Miguel EC, Ferrão YA, Rosário MC, Mathis MA, Torres AL, Fontenelle LF, et al. The Brazilian Research Consortium on Obsessive-Compulsive Disorders: recruitment, assessment instruments, methods for the development of multicenter collaborative studies and preliminary results. Rev Bras Psiq. 2008;30(3):185-96.
5. Almeida Filho N, Mari JJ, Coutinho E, França JF, Fernandes JF, Andreoli SB, et al. Estudo multicêntrico de morbidade psiquiátrica em áreas urbanas brasileiras (Brasília, São Paulo, Porto Alegre). Revista ABP-APAL. 1992;14(3):93-104.
6. Organização Mundial da Saúde. Classificação Estatís- tica Internacional de Doenças e problemas relacionados à saúde: CID-10. 10. ed. São Paulo: USP; 2007.
7. De Hann E, van Oppen P, van Balkom AJLM, Spinhoven P, Hoogduin KAL, Van Dyck R, et al. Prediction of outcome and early vs. Late improvement in OCD patients treated
1. with cognitive behaviour therapy and pharmacotherapy. Acta Psychiatr Scand. 1997;96(5):354-61.
8. Refractory. Encyclopaedia Britannica Company. Merriam-Webster. 2014 [capturado em 01 ago. 2014]. Disponível em: http://www.merriam-webster.com/ dictionary/refractory.
9. Resistant. Encyclopaedia Britannica Company. Merriam-Webster. 2014 [capturado em 01 ago. 2014]. Disponível em: http://www.merriam-webster.com/ dictionary/resistant.
10. Turón VJ, Salgado P. Estrategias terapéuticas en el trastorno obsesivo-compulsivo refractario. In: Ruiloba JV, Berrios GE, editores. Estados Obsesivos. 2. ed. Barce- lona: Masson; 1995. p. 397-416.
11. Rauch SL, Jenike MA. Management of treatment resistant obsessive compulsive disorder: concepts and strategies. In: Textbook from the proceedings of the 1st IOCDC. Capri: [s.n.]; 1993. p. 12-13.
12. Schindler KM, Pato MT. Clomipramine. In: Current Treatments of Obsessive-compulsive disorder. Washing- ton: APA; 2001. p. 19-37.
13. Cordioli AV. Cognitive-behavioral therapy in obsessive-compulsive disorder. Rev Bras Psiquiatr. 2008;30(suppl.2):s65-s72.
14. Pallanti S, Hollander E, Bienstock C, Koran L, Leckman J, Marazziti D, et al. International Treatment Refractory OCD ConsortiumTreatment non-response in OCD: methodological issues and operational definitions. Int J Neuropsychopharmacol. 2002;5(2):181-91.
15. Goodman WK, McDougle CJ, Barr LC, Aronson SC, Price LH. Biological approaches to treatment-resistant Obsessive-Compulsive Disorder. J Clin Psychiatry. 1993; 54(6 suppl):16-26.
16. DeVaugh-Geiss J, Katz R, Landau P, Goodman W, Rasmussen S. Clinical predictors of treatment response in obsessive compulsive disorder: exploratory analyses from multicenter trials of clomipramine. Psychopharm bull. 1990;26(1):54-9.
17. Moreno AC, Calo JJP, Pinero MV, zaragoza CL, Navarro VF Marsa MD. Evolución y respuesta terapéutica en el Transtorno Obsesivo-Compulsivo. Actas Luso esp Neurol Psiquiatr Cienc Afines. 1995;23(1):9-19.
18. Ferrão YA, Shavitt RG, Bedin NR, de Mathis ME, Lopes AC, Fontenelle LF, et al. Clinical features associated to refractory obsessivecompulsive disorder. J Affect Disord. 2006;94(1-3):199-209.
19. Dougherty DD, Baer L, Cosgrove GR, Cassem EH, Price BH, Nierenberg AA, et al. Prospective Long-Term Follow- Up of 44 Patients Who Received Cingulotomy for Treatment-Refractory Obsessive-Compulsive Disorder. Am J Psychiatry. 2002;159(2):269–75.
20. Murray CL, Lopez AD. The global burrion of diseases: a comprehensive assesment of mortality and disability from diseases. Cambridge: Harvard University Press; 1996.
21. Greenberg WM, Benedict MM, Doerfer J, Perrin M, Panek L, Cleveland WL, et al. Adjunctive glycine in the treatment of obsessive-compulsive disorder in adults. J Psychiatr Res. 2009;43(6):664-70.
22. Torres AR, Ramos-Cerqueira ATA, Ferrão YA, Fontenelle LF, Rosário MC, Miguel EC. Suicidality in obsessive-compulsive disorder: prevalence and relation to symptom dimensions and comorbid conditions. J Clin Psych. 2011;72(1):17-26.
23. Ferrão YA, Florão MS. Acomodação familiar e criticismo percebido em pacientes com transtorno ob- sessivo-compulsivo. J Bras Psiquiatr. 2010;59(1): 34-43.
24. Foa EB. Cognitive behavioral therapy of obsessive- compulsive disorder. Dialogues Clin Neurosci. 2010;12(2):199-207.
25. Ferrão YA, Diniz JB, Lopes AC, Shavitt RG, Greenberg B, Miguel E. Resistance and refractoriness in obsessive- compulsive disorder. Rev Bras Psiquiatr. 2007;29(Suppl 2):S66-76.
26. Pampaloni I, Sivakumaran T, Hawley CJ, Al Allaq A, Farrow J, Nelson S, et al. High-dose selective serotonin reuptake inhibitors in OCD: A systematic retrospective case. J Psychopharmacol. 2010;24(10):1439-45.
27. The British Psychological Society, The Royal College of Psychiatrists. Obsessive-compulsive disorder: core interventions in the treatment of obsessive-compulsive disorder and body dysmorphic disorder. National Collaborating Centre for Mental Health. London: British Psychological Society, Royal College of Psychiatrists; 2006.
28. Bloch MH, Landeros-Weisenberger A, Kelmendi B, Coric V, Bracken MB, Leckman JF. A systematic review: antipsychotic augmentation with treatment refractory obsessive-compulsive disorder. Mol Psychiatry. 2006;11(7):622-32.
29. Hollander E, Bienstock CA, Koran LM, Pallanti S, Marazziti D, Rasmussen SA, et al. Refractory Obsessive- compulsive disorder: state-of-art treatment. J Clin Psychiatry. 2002;63(6 suppl):20-9.
30. Decloedt E, Stein DJ. Current trends in drug Treatment of obsessive-compulsive disorder. Neuropsychiatr Dis Treat. 2010;6:233-42.
31. Diniz JB, Shavitt RG, Fossaluza V, Koran L, Pereira CA, Miguel EC. A double-blind, randomized, controlled trial of fluoxetine plus quetiapine or clomipramine versus fluoxetine plus placebo for obsessive-compulsive disorder. J Clin Psychopharmacol. 2011;31(6):763-8.
32. Koran LM, Aboujaoude E, Bullock KD, Franz B; Gamel N, Elliott M. Double-blind treatment with oral morphine in treatment-resistant obsessive-compulsive disorder. J Clin Psychiatry. 2005;66(3):353-9.
33. Zdanys K, Tampi RR. A systematic review of off-label uses of memantine for psychiatric disorders. Prog Neuropsychopharmacol Biol Psychiatry. 2008;32(6):1362- 74.
34. Dell’osso B, Mundo E, Marazziti D, Altamura AC. Switching from serotonin reuptake inhibitors to duloxetine in patients with resistant obsessive compulsive disorder: a case series. J Psychopharmacol. 2008;22(2):210-3.
35. Berlin HA, Koran LM, Jenike MA, Shapira NA, Chaplin W, Pallanti S, et al. Double-blind, placebo-controlled trial of topiramate augmentation in treatment-resistant obsessive-compulsive disorder. J Clin Psychiatry. 2011;72(5):716-21.
36. Harvey BH, Scheepers A, Brand L, Stein DJ. Chronic inositol increases striatal D(2) receptors but does not modify dexamphetamine-induced motor behavior. Relevance to obsessive-compulsive disorder. Pharmacol Biochem Behav. 2001;68(2):245-53.
37. Pallanti S, Bernardi S, Antonini S, Singh N, Hollander E. Ondansetron augmentation in treatment-resistant obsessive-compulsive disorder: a preliminary, single- blind, prospective study. CNS Drugs. 2009;23(12):1047- 55.
38. Amiaz R, Fostick L, Gershon A, Zohar J. Naltrexone augmentation in OCD: a double-blind placebo-controlled cross-over study. Eur Neuropsychopharmacol. 2008;18(6):455-61.
39. Miguel E.C.; Gentil V.; Gattaz W.F. et al .Clinica psiquiatrica – a visão do departamento e do instituto de psiquaitria do HCFMUSP. 2011.
40. Carvalho A.F; Nardi A.E.; Quevedo J. et al. Transtornos psiquiátricos resistentes ao tratamento. Diagnóstico e Manejo. 2015.